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cotransporter 2 (SGLT-2) inhibitors currently approved for use in type 2 diabetes. Phase III trials for all 
agents were included. All English-language articles from 2010 to 2015 appearing in these searches were 
reviewed for relevance to this paper. In addition, related articles suggested in the PubMed search were 
also reviewed. The SGLT-2 inhibitors have shown a reduction in hemoglobin A1c values and fasting 
plasma glucose levels with a low incidence of hypoglycemia. The incidence of mycotic infections is 
increased in patients taking an SGLT-2 inhibitor. 
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SGLT-2 Inhibitors: A Novel Mechanism 
in Targeting Glycemic Control in Type 2 
Diabetes Mellitus
Kobi T. Nathan, Nabila Ahmed-Sarwar, Paul Werner
OBJECTIVE: To review the chemistry, pharmacology, pharma­
codynamics, pharmacokinetics, clinical efficacy, tolerability, 
dosing, drug interactions, and administration of canagliflozin, 
dopagliflozin, and empagliflozin, and comparing the benefit 
and risk aspects of using these agents in the older adult diabe­
tes patient population.
DATA SOURCES, STUDY SELECTION, DATA EXTRACTION,
AND DATA SYNTHESIS: A search of PubMed using the 
terms "SGLT-2 inhibitors," "canagliflozin," "dopagliflozin," 
"empagliflozin," "efficacy," and "tolerability" was performed to 
find relevant primary literature on each of the sodium/glucose 
cotransporter 2 (SGLT-2) inhibitors currently approved for use 
in type 2 diabetes. Phase III trials for all agents were included.
All English-language articles from 2010 to 2015 appearing in 
these searches were reviewed for relevance to this paper. In 
addition, related articles suggested in the PubMed search were . 
also reviewed. The SGLT-2 inhibitors have shown a reduction 
in hemoglobin Ale values and fasting plasma glucose levels 
with a low incidence of hypoglycemia. The incidence of mycotic 
infections is increased in patients taking an SGLT-2 inhibitor. 
CONCLUSION: SGLT-2 inhibitors may be a viable treatment 
option for patients not controlled on other oral agents. The risk 
of hypoglycemia is small. However, the clinical efficacy and 
tolerability of these agents has not been fully elucidated in 
older and frail patients.
KEY WORDS: Anti-hyperglycemic agents, Canagliflozin, 
Dopagliflozin, Empagliflozin, Hypoglycemia, SGLT-2 inhibitors. 
Type 2 diabetes mellitus.
ABBREVIATIONS: ADA = American Diabetes Association, ADC = 
Area under the curve. Cl = Confidence interval, CYP = Cytochrome 
P450, DPP-4 = Dipeptidyl peptidase-4, eGFR = Estimated glomeru­
lar filtration rate, FAERS = Federal Drug Administration Adverse 
Event Reporting System, FDA= Food and Drug Administration,
FPG = Fasting plasma glucose, HbAlc = Hemoglobin Ale, SGLT-2 
= Sodium/glucose cotransporter 2, T2DM = Type 2 diabetes 
mellitus, UGT = UDP-glucuronosyltransferase, UTI = Urinary tract 
infection, Vj = Volume of distribution.
Consult Pharm 2016;31:251-260.
Introduction
The long-term glycotoxic effects of persistent 
hyperglycemia in type 2 diabetes (T2DM) is well-known 
and documented. Treating hyperglycemia can be an 
arduous and complicated process for both the provider 
and the patient. A myriad of oral anti-hyperglycemic 
agents, in addition to insulin, are available to return 
patients to normoglycemia. The majority of these agents 
(metformin, sulfonylureas, nonsulfonylurea secretagogues, 
glucagonlike peptide-1 analog, and dipeptidyl peptidase-4 
[DPP-4] inhibitors) are insulin-dependent.' Their efficacy 
diminishes over time as pancreatic islet (3-cell function 
declines over the natural progression of the disease.'’^
In addition, use of these agents has its limitations, 
such as increased risk of hypoglycemia and weight 
gain with insulin and sulfonylureas.^-^ Treating older 
adults with T2DM poses significant pharmacologic 
hurdles and challenges. Complex pharmacodynamic 
and pharmacokinetic variables come into play, such 
as multiple comorbidities, drug-disease interactions, 
drug-drug interactions, polypharmacy, and altered 
pharmacokinetics as a result of changes in metabolic 
function, adipose, and lean tissue composition.
A novel class of oral anti-hyperglycemic agents, the 
SGLT-2 (sodium/glucose cotransportor-2) inhibitors 
may hold promise in managing older adults with T2DM, 
especially when used as an adjunct to established oral 
agents. SGLT-2 inhibitors have an insulin-independent 
mechanism of action, which differentiates them from the 
other oral anti-hyperglycemic agents. The blood glucose­
lowering efficacy of the SGLT-2 inhibitors in T2DM has 
been clinically demonstrated in prospective randomized 
clinical trials.'-’ * This effect is seen when the SGLT-2 
inhibitors are administered as monotherapy or as adjunct 
agents with other glucose-lowering medications." Rapid 
de-escalations in both basal and postprandial blood 
glucose levels are seen, with decreases of hemoglobin Ale 
(HbAlc) averaging 0.6% to 1.2%, with the potential to 
decrease up to 3% in patients with severely uncontrolled 
diabetes.’ '" There are currently three agents in the SGLT- 
2 inhibitor drug class: canagliflozin, dapagliflozin, and 
empagliflozin." '’ Several more agents that are currently in 
development are listed in Table 1.'’ “
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Table 1. SGLT-2 Inhibitors in Development
Agent
Ar’isil ' '
Development Phase*
i Ertugliflozin Phase III
’ Ipragliflozin Phase III
Luseogliflozin Phase III
Remogliflozin Phase lib
’ Tofogliflozin Phase III
I Abbreviation: SGLT-2 = Sodium/glucose cotransporter 2.
I • Phase III = Confirms effectiveness, monitors side effects, identifies
I indications, and identifies safety parameters 
i • Phase Mb = Establishes efficacy and further evaluates safety 
; Source: References 16-20.
Chemistry
Canagliflozin: The empirical formula is 
C24H25F05S*1/2H20, with a molecular weight of 453.53 
(Figure 1).'^ The agent is available in a film-coated tablet 
for oral administration with either 102 or 306 mg of the 
active drug, equating to 100 and 300 mg of anhydrous 
canagliflozin, respectively. Canagliflozin is practically 
insoluble in aqueous media from pH 1.1 to 12.9." '^ 
Dapagliflozin: The empirical formula is 
C2iH25C106'^C3H802*H20, with a molecular weight 
of 502.98 (Figure 2).'^ It is available in a film-coated 
tablet for oral administration with either 5 or 10 mg 
of the active drug, dapagliflozin propanediol.'^ ''* 
Empagliflozin: The empirical formula is C21H25CIO6, 
with a molecular weight of 450.91 (Figure 3).^' It is 
available in a film-coated tablet for oral administration 
with either 10 or 25 mg of the active drug base.'^'^'
Clinical Pharmacology
SGLT-2 is a protein transporter responsible for 
approximately 90% of glucose reabsorption at the 
proximal renal tubule. Under normal physiological 
conditions, the Na-t/K-i- ATPase pump, located 
basolaterally within the renal tubules, uses adenosine 
triphosphate (ATP) to shuttle three sodium ions to 
the blood while bringing two potassium ions into the 
intracellular space. This mechanism decreases the 
sodium content inside the cell and drives the SGLT- 
2 pump to bring sodium and glucose into the cell. As
Figure 1. Structural Formula of 
Canagliflozin
Source: Reference 12.
Figure 2. Structural Formula of 
Dapagliflozin
Source: Reference 14.
Figure 3. Structural Formula of 
Empagliflozin
Source: Reference 21.
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this pump transports glucose into the cell against its 
gradient, its action is considered to be secondary active 
transport. The pump cotransports sodium and glucose 
at 1:1 stoichiometry from the lumen to the intracellular 
space, after which time GLUT-2 brings the reabsorbed 
glucose from the intracellular space to the peritubular 
capillaries, thereby increasing plasma glucose levels.’’" '^-^' 
SGLT-2 has a high capacity, but low affinity for glucose. 
SGLT-2 inhibitors bind to SGLT-2, preventing them 
from exerting their action of glucose reabsorption. The 
result is a greater amount of glucose remaining in the 
urine and subsequently excreted from the body. SGLT- 
2 is responsible for approximately 90% of total glucose 
reabsorption, and it is estimated that the effect of the 
SGLT-2 inhibitors account for a decrease in glucose 
reabsorption of about
Pharmacokinetics
The pharmacokinetic profiles for each of the three SGLT-2 
inhibitors are detailed in Table
Clinical Efficacy
Several trials have evaluated the clinical efficacy and 
tolerability of the three current SGLT-2 inhibitors 
approved by the Food and Drug Administration (FDA) 
for the treatment of T2DM. Studies have evaluated 
this class of medication in comparison to lifestyle 
modifications and various other oral anti-hyperglycemic 
agents, including sulfonylureas, metformin, and DPP- 
4 inhibitors.This class of medications is not 
approved as an add-on therapy to insulin. Overall, each 
individual agent has shown a reduction in HbAlc values 
and fasting plasma glucose levels with a low incidence of 
hypoglycemia.^’^'*
Table 2. Pharmacokinetics of SGLT-2 Inhibitors
Conoglifiozin flnvokonoj^^ Jlapogliflozin (Forxigo) Empogliflozlp (Jordionce)
Onset of action Within 24 hours
(dose-dependent)
Within 24 hours Peak plasma: within 1.5 h 
postdose
Duration of action 24 hours 24 hours 24 hours
Absorption Not affected by food; 
taking before first meal 
! may decrease postprandial 
: hyperglycemia
High-fat meal decreases 
peak plasma concentration 
by up to 50%
Lower absorption with high- 
fat and high-calorie meal; 
AUC 4-16%, but not clinically 
significant
Distribution ^ Vd:119 L Vj: 118 L Vj: 73,8L
Protein binding 99% mainly to albumin 91% 86.2%
Metabolism O-glucuronidotion by
UGT1A9&UGT2B4to2
inactive metabolites; minor
CYP3A4 oxidation
UGT 1A9 to 1 inactive 
metabolite (Dopagliflozin 
3-O-glucuronide), minor CYP
Glucuronidation by
UGT28T, UGT1A2, UGT1A3, 
UGHT1A8, UGT1A9
Bioovoilobility - 65% 78% N/A
Half-life elimination 100 mg: 10.6 hours
300 mg: 13.1 hours
12.9 hours 12.4 hours
Time to peak 1-2 hours 2 hours 1.5 hours
Excretion Feces (51.7%) Urine (75%) Urine (54.4%)
Urine (- 33%) Feces (21%) Feces (41.2%)
Abbreviations; AUC = Area under the curve, CYP = Cytochrome P450, SGLT-2 inhibitors = Sodium/glucose cotransporter 2, 
UGT = UDP-glucuronosyltransferase, Vj = Volume of distribution.
Source: References 11-15, 21,
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Canagliflozin
Patients with an average HbAlc of 8% who were 
randomized to canagliflozin 100 mg daily, 300 mg daily, 
or diet and exercise/placebo; canagliflozin 300 mg 
once daily produced clinically significant reduction in 
HbAlc with absolute reduction of 1.03% at 26 weeks. In 
comparison, the 100 mg daily dose achieved an absolute 
HbAlc reduction of 0.77% at 26 weeks. Additionally, 
the reduction in fasting plasma glucose levels of 27 mg/ 
dL and up to 34 mg/dL in the canagliflozin 100 mg daily 
and 300 mg daily groups, respectively, was observed.
The authors concluded that both the 100 mg and 300 
mg dosing regimens provided clinical and statistically 
significant improvements in glycemic control. While 
acknowledging the ability to improve glycemic targets, 
the baseline average fasting plasma glucose levels ranged 
from 166 to 172 mg/dL, and even at doses of 300 mg daily, 
patients were unable to reach goal fasting blood glucose 
levels between 80 and 130 mg/dL as recommended by 
the American Diabetes Association.Acknowledging 
that goals should be individualized for each patient, the 
reduction observed with canagliflozin may be clinically 
significant in certain patient populations. Clinical trials 
including patients with average baseline HbAlc values 
ranging from 7.8% to 7.9% determined that canagliflozin 
as an add-on therapy to metformin was not inferior in 
comparison to glimepiride plus metformin or sitagliptin 
plus metformin in reducing HbAlc and fasting plasma 
glucose (PPG) values. At 52 weeks, canagliflozin 100 
mg daily plus metformin did not produce a clinically 
significant reduction in HbAlc values (0.01%; 95% 
confidence interval [Cl] -0.11%-0.09%). Canagliflozin 300 
mg daily plus metformin resulted in an absolute HbAlc 
reduction of approximately 0.12% (95% Cl -0.22% to 
-0.02%) compared with patients randomized to either 
glimepiride plus metformin or sitagliptin plus metformin. 
The results of these studies indicate the combination of 
canagliflozin and metformin does not provide greater 
benefits in glycemic control compared with previously 
available medication classes.^'^
Dapagliflozin
Similar efficacy is demonstrated in noninferiority trials 
evaluating dapagliflozin.^^'^‘‘ The safety and efficacy 
of dapagliflozin has been evaluated in comparison to 
metformin, as an add-on to metformin or sulfonylureas, 
and as add-on therapy to metformin and sitagliptin.
Patients with T2DM inadequately controlled on 
metformin were randomized to receive dapagliflozin 5 
mg and 10 mg in addition to continuing their high-dose 
metformin therapy.^^ A reduction in HbAlc of 0.7% in 
patients receiving 5 mg and 0.84% in patients receiving 10 
mg from an average baseline HbAlc of 8.1% was observed 
at 24 weeks, in comparison to an HbAlc reduction of 0.3% 
seen in patients continuing metformin monotherapy. The 
addition of high-dose dapagliflozin has demonstrated 
the overall ability to provide an additional 0.54% HbAlc 
decrease in comparison to metformin alone. In a small 
subset of patients with baseline HbAlc values > 9%, 
an overall reduction of 0.84% in HbAlc was observed 
at 24 weeks when compared with patients receiving 
metformin monotherapy. The absolute difference in PPG 
in patients receiving the combination of dapagliflozin and 
metformin was no greater than 17 mg/dL when compared 
with metformin monotherapy. The authors of this study 
concluded at 24 weeks that the addition of dapagliflozin to 
patients inadequately controlled on metformin resulted in 
a significant reduction in HbAlc and PPG. Acknowledging 
that a statistically significant improvement is observed, 
the limited HbAlc reduction achieved may have an 
inadequate impact on reducing long-term complications 
of diabetes. The potential for a greater HbAlc reduction 
observed in patients with higher baseline HbAlc values 
may provide a greater clinical impact.
Additionally, dapagliflozin has been studied as an 
add-on therapy for patients inadequately controlled on 
glipizide or glimepiride.^^'^"* Patients with an average 
baseline HbAlc of 7.8% did not achieve a statistically or 
clinically relevant difference in HbAlc reduction when 
comparing dapagliflozin 10 mg with glipizide (-0.5% vs. 
-0.52%; P = NS, respectively).^"* In patients with a baseline 
HbAlc of approximately 8.1%, the difference in HbAlc 
reduction was observed to be no greater than 0.27% when 
comparing patients receiving dapagliflozin in addition to
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glimepiride versus glimepiride monotherapy. Although a 
greater HbAlc reduction was seen in patients receiving 
the combination, approximately 30% of these patients 
required additional therapies as a result of poor control, 
indicating that the additional HbAlc reduction cannot be 
contributed to the addition of dapagliflozin alone.^’
In contrast to the findings of canagliflozin, dapagliflozin 
in addition to sitagliptin + metformin compared with 
sitagliptin ± metformin demonstrated an additional 
reduction of 0.4% from baseline in patients with baseline 
HbAlc of 7.9% at 24 weeks. Dapagliflozin did demonstrate 
that patients with baseline HbAlc > 8% achieved a 
greater HbAlc reduction from baseline of 0.8% and 
absolute reduction in fasting plasma glucose of -27.9 mg/ 
dL compared with placebo. The authors concluded the 
addition of dapagliflozin in patients inadequately controlled 
on sitagliptin with or without metformin therapy provides 
additional clinical benefits.* Although the clinical benefit 
of an overall reduction of 0.4% is questionable, the greater 
Ale reduction observed in patients with higher baseline 
HbAlc levels may provide a greater clinical impact in 
prevention of long-term complications of hyperglycemia.
Empagliflozin
In contrast, the most recently FDA-approved SGLT-2 
inhibitor, empagliflozin, has been largely studied as an 
add-on therapy to metformin, being compared with the 
combination of metformin with either a sulfonylurea or 
DPP-4 inhibitor.“ When compared with placebo plus 
metformin as an add-on to metformin, empagliflozin 10 
mg daily and 25 mg daily plus metformin produced similar 
absolute HbAlc reductions, 0.57% and 0.64%, respectively, 
at 24 weeks."* Similarly, when both strengths of empagliflozin 
plus metformin were compared with sitagliptin plus 
metformin, the HbAlc reductions achieved were 
consistent with those found when compared with placebo 
plus metformin and remained consistent at 78 weeks.* A 
comparison of empagliflozin 25 mg daily plus metformin 
and glimepiride plus metformin found no difference in 
reducing HbAlc levels between the two treatment groups.*^* 
The overall reductions in FPG seen with empagliflozin in 
clinical trials, regardless of comparator, were similar to those 
in trials evaluating canagliflozin.
In a subgroup analysis of patients with baseline HbAlc 
> 10% (n = 69), a significantly greater absolute HbAlc 
reduction of 3.23% and FPG reduction of 38 mg/dL 
compared with placebo was achieved. This indicates the 
potential for empagliflozin to provide a greater impact 
on improving glycemic control in patients with higher 
baseline HbAlc levels.^ A limitation of these findings 
is the study protocol allowed for the use of rescue 
medication use in patients with elevated fasting blood 
glucose levels or patients with HbAlc > 8.5% at scheduled 
follow-ups during the 24-week period. The empagliflozin 
trials concluded a significant improvement in glycemic 
control compared with other oral anti-hyperglycemic 
agents."*'*'^* The subgroup analysis of patients with 
HbAlc > 10% provides compelling data to hypothesize 
hyperglycemia-dependent clinical efficacy.
Tolerability
SGLT-2 inhibitors have demonstrated to be well tolerated 
in clinical trials, resulting in a low study-withdrawal rate.*' 
5,8,22 qijg trials consistently reported no significant changes 
in renal function and serum electrolytes in patients 
randomized to either SGLT-1 inhibitors or comparator 
oral anti-hyperglycemic agents. This is in contrast to the 
postmarketing reports and subsequent FDA warning 
regarding the increase in risk of ketoacidosis associated 
with this class of medication.*®
In early 2016, FDA added new warnings and precautions 
to labels of all SGLT-2 inhibitors following a review of the 
FDA Adverse Event Reporting System (FAERS) database 
from March 2013 to May 2015. Seventy-three cases of 
ketoacidosis in patients with type 1 and type 2 diabetes 
were reported. Presentation was serious enough to warrant 
hospitalization or treatment in the emergency department. 
In several instances, ketoacidosis was not identified, and 
treatment was delayed because of patients presenting in a 
euglycemic state. Additionally, 19 cases of life-threatening 
urosepsis and pylenonephritis were added to the FAERS 
database from March 2013 to October 2014. All patients 
required hospitalization, with some requiring admission to 
an intensive care unit or dialysis to treat acute kidney injury.*® 
The rates of hypoglycemia for patients randomized to 
receive this class of medication was not significantly different
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Table 3. Reports of Adverse Drug Reactions
Percentage of patients reporting adverse drug reaction for each agent
Adverse Drug 
Reaction
Dapagliflozin + 
Metformin
Empagliflozin 
-1- Metformin
Canagliflozin -i-
Metformin
Metformin Sitagliptin +
Metformin
Glimepiride + 
Metformin
Hypoglycemia 2%-4% 1.8%-2.4%
(0.9%-1.8%
monotherapy)
2%-6% 0.5%-3.6% 3.6%-5% N/A
Osmotic
diuresis
N/A N/A 3%-5% N/A N/A < 1%
UTIs 4%-8% 9%-12.7%
(3.8%-6.4%
monotherapy)
6%-12% 4.9%-8% 12.5% 5%
Genital
infections
8%-13% 3%-3.6%
(3.7%-5.8%
monotherapy)
3%-11.1% 0%-5% 0% 1.6%
Abbreviations: N/A = Not reported in 
Source: References 3-5, 8, 9.
study, UTI = Urinary tract infection.
in comparison to metformin, sitagliptin, and sulfonylureas.^'^ 
The reported increase in urinary glucose excretion of 
approximately 20 g in patients receiving an SGLT-2 inhibitor 
in comparison to metformin.^ Adverse reactions resulting 
from an increase in glucose in the renal and genital urinary 
tract can be expected. Adverse drug reactions such as 
occurrence of urinary tract infections (UTIs), genital 
infections, and osmotic diuresis for each of the SGLT-2 
inhibitors are listed in Table 3. No significant difference in 
the occurrence of osmotic diuresis was observed in patients 
randomized to receive SGLT-2 inhibitors.^ ®
The occurrence of UTIs for all three agents—dapaglif- 
lozin, empagliflozin, and canagliflozin—was not different 
when compared with metformin or glimepiride after 24 
weeks of therapy.’ Patients receiving empagliflozin were 
followed for an extended duration of 78 weeks; the rate 
of UTIs were lower in patients receiving empagliflozin 
monotherapy in comparison to those on combination 
empagliflozin and metformin (3.8%-6.4% vs. 12.7%). No 
significant difference in the rate of UTIs was observed 
in patients receiving empagliflozin and metformin in 
comparison to those receiving sitagliptin and metformin 
(12.7% vs. 12.5%, respectively).®
Unlike UTIs, the reports of genital infections 
described as mild to moderate were significantly higher 
in patients receiving SGLT-2 inhibitors in comparison 
to metformin, sitagliptin, and sulfonylureas.®‘® “ In 
comparison to canagliflozin and dapagliflozin, the reports 
of genital infections occurred less frequently in patients 
receiving empagliflozin, with a higher incidence in female 
than male patients.
SGLT-2 inhibitors were associated with reductions in 
systolic blood pressure; reductions were slightly higher 
when SGLT-2 inhibitors were used in combination with 
metformin therapy.'*'^^'^®'^® The greatest reduction in systolic 
blood pressure was reported to be 5.4 mmHg from baseline 
in patients randomized to receive canagliflozin 300 mg 
daily.“ Reports of orthostatic hypotension were reported 
in < 1% of patients randomized to canagliflozin as an add­
on to metformin in comparison to no reports in patients 
receiving glimepiride and metformin.® At 48 weeks, no 
difference was found between patients randomized to 
dapagliflozin as an add-on therapy to sitagliptin with or 
without metformin in the occurrence of hypotension, 
dehydration, and hypovolemia.®
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Drug Interactions
Drug interactions with SGLT-2 inhibitors are relatively 
limited in comparison to other oral anti-hyperglycemic 
agents.The potential to enhance the hypoglycemic 
effects of SGLT-2 inhibitors is possible when combined 
with insulin and insulin secretagogues.^' Initiating lower 
doses of the SGLT-2 inhibitors in combination with 
reduction in dose of prandial insulin doses and short­
acting sulfonylureas can reduce the risk of hypoglycemic 
events. Additionally, the potential for osmotic diuresis 
leading to volume depletion, resulting from increases 
in urine volume and polyuria, is higher in patients 
concurrently receiving SGLT-2 inhibitors and diuretics.^* 
Dose reductions of loop diuretics (i.e., furosemide and 
torsemide) should be considered when concurrently 
used with SGLT-2 inhibitors. Drug interactions specific 
to canagliflozin include UDP-glucuronosyltransferase 
(UGT) enzyme inducers and digoxin. Concurrent use 
of nonselective UGT enzyme inducers (i.e., rifampin, 
phenytoin, phenobarbital, ritonavir) significantly reduces 
the area under the curve (AUC) of canagliflozin. Patients 
on concurrent UGT enzyme-inducer therapy are likely to 
require canagliflozin 300 mg daily to achieve therapeutic 
drug levels.'^ Additionally, canagliflozin has the potential 
to increase the AUC and mean peak drug concentration 
of digoxin.'^ Monitoring digoxin levels in patients 
receiving concurrent digoxin and canagliflozin therapy
after initiation or adjustments in canagliflozin dosing can 
be utilized to monitor for digoxin toxicity. Canagliflozin 
did not inhibit 1A2, 2A6, 2C19, or 2E1 isoenzymes and 
weakly inhibited 2B6, 2C8, 2C9, and 3A4.
Dosing and Administration
The currently available dosage formulations for 
products containing SGLT-2 inhibitors are available in 
Table 4.>2,14.21,29-31 medication is approved for
use in patients with T2DM and has primarily been studied 
in individuals older than 18 years of age. No specific 
hepatic dosage adjustments are required in patients with 
hepatic impairment. The efficacy of this medication 
class is significantly dependent on renal clearance; the 
recommendations are based on estimated glomerular 
filtration rate (eGFR) for each agent and vary slightly.
All three agents are determined to be safe and efficacious 
in patients with eGFR > 60 mL/min.‘^ '‘'’^''^^^' The use 
of dapagliflozin is not recommended in patients with 
eGFR < 60 mL/min.''* Canagliflozin and empagliflozin 
are not recommended in patients with an eGFR < 45 
mL/min.‘^'^' The dose of canagliflozin should not exceed 
100 mg daily in patients with eGFR between 45-59 mL/ 
min.‘^ To maximize efficacy it is ideal to instruct patients 
to administer these medications once daily prior to their 
morning meal. Appropriate adjustments to timing of the 
medication should be made for patients to align with
Table 4. Commercially Available Formulation of SGLT-2 Inhibitors
Product 4|- Avallgble strengths Frequency of administration
Farxiga (dapagliflozin) 5 mg and 10 mg tablets Every morning
Invokana (canagliflozin) 100 mg and 300 mg tablets Every morning
Jardiance (empagliflozin) 10 mg and 25 mg tablets Every morning
Combination products
Xigduo XR (dapagliflozin/metformin) 5/500 mg, 5/1,000 mg, 10/500 mg, 
10/5,000 mg tablets
1 Every morning
Invokamet (canagliflozin/metformin) 50/500 mg, 50/1,000 mg, 150/500 
mg, 150/5,000 mg tablets
1 Every morning
Glyxambi (empagliflozin/linagliptin) 10/5 mg, 25/5 mg tablets j Every morning
Abbreviation: SGLT-2 = Sodium/glucose 
Source: References 12, 14, 21, 33-35.
cotransporter 2.
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timings when dietary intake is consistent with a longer 
duration of time (i.e., night-shift workers).
Pharmacoeconomics
Currently, there are no pharmacoeconomic studies 
comparing the cost-effectiveness of the SGLT-2 inhibitors 
as a drug class. The average wholesale price pricing for 
each agent in this drug class is outlined in Table
Discussion and Recommendations
Overall, SGLT-2 inhibitors have been shown to reduce 
HbAlc values and FPG levels with a low incidence of 
hypoglycemia. The safety and efficacy of each agent in 
this novel drug class has been evaluated against the other 
established oral antidiabetic agents, such as metformin, 
the sulfonylureas, and the DPP-4 inhibitors. However, for 
patients with HbAlc 7.8%-8.1%, the clinical significance 
of these reductions may prove to be questionable in the 
larger scenario of effective glycemic control in patients 
with type 2 diabetes. Notably, the modest reduction in 
HbAlc percentage for each agent as discussed in the 
various studies fail to make a clinically relevant reduction 
in HbAlc values, limiting their benefits to patients within 
1% from achieving their goal HbAlc. However, the SGLT- 
2 inhibitor class has demonstrated, but not established, 
the possibility of providing a greater HbAlc reduction 
in patients with significantly elevated HbAlc values 
(> 10.0%), suggesting a potential to provide clinically 
significant reductions in HbAlc values in this subset 
of diabetic patients."* For these individuals, the SGLT-2 
inhibitors may provide a viable alternative to insulin 
therapy. Conversely, cost may prove to be prohibitive in its 
use as an adjunct treatment option; the cost of insulin is 
significantly less than this novel class of agents. Providers 
and patients will have to weigh the benefits versus risks of 
insulin therapy over SGLT-2 inhibitor therapy.
Clinical studies suggest that the SGLT-2 inhibitors 
are well-tolerated by patients, with the most common 
events being osmotic diuresis and mycotic infections. The 
incidence of these adverse events was low in the trials; 
however, the average age of patients included in currently 
available SGLT-2 inhibitor studies ranged from 51.0 to 
60.8 years. The limited number of patients older than 70
Table 5. Approximate Cost of 
SGLT-2 Inhibitors
Agent . Wfiol Dose* „
Canagliflozin (Invokana) 100 mg once daily ($340)
Dapagliflozin (Farxigo) 5 mg once doily ($340)
Empogliflozin (Jordionce) 10 mg once doily ($340)
* Approximate cost for 30-day supply.
Abbreviation: SGLT-2 = Sodium/glucose cotransporter 2. 
Source; Reference 32.
Table 6. Education Points for Patients on 
SGLT-2 Inhibitor Therapy
1 Adverse Drug
I Reaction
Signs and Symptoms Requiring 1 
Referral to Clinician [I.
Mycotic infections • Vaginal itching or burning
• Abnormal vaginal discharge
• Urinary frequency
Urinary tract infections • Urinary frequency
• Flank pain
• Fever
• Dysuria
• Urinary frequency
Hypovolemia • Orthostasis
• Dizziness
• Elevated skin turgor
• Dry mucus membranes
Renal dysfunction
i
• Dark urine
• Weakness/fatigue
• Urinary frequency
• Hypotension
Ketoacidosis • Mental confusion
• Extreme fatigue
• Nausea and vomiting
• Abdominal pain
• Hyperventilation
Source: References 12, 14, 21.
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years of age poses a challenge in extrapolating the safety 
endpoints in geriatric patients.* Consequently, the safety 
and efficacy of these agents has not been ascertained in the 
older and frail patient population with multiple comorbid 
conditions. Older patients, because of natural biophysical 
changes, are more prone to the deleterious effects of 
dehydration and UTIs. Use of the SGLT-2 inhibitors, with 
resultant osmotic diuresis, decreased intravascular volume, 
and possible electrolyte derailment, may lead to potentially 
harmful consequences in older adults. In addition, older 
patients, especially women and those with diabetes, are 
at increased risk for genital infections. An increase in 
rates of such events has been reported in all studies of the 
SGLT-2 inhibitors.*'^ * Older adults manifest hypoglycemia 
differently than the general younger population, and are 
also more prone to its effects. The consequences of these 
adverse drug reactions have the potential to cause harm 
to elderly patients. Pharmacists should ensure patients are 
adequately educated on signs and symptoms that indicate 
the need for provider intervention, as listed in Table 6. 
While the studies show a low incidence of hypoglycemic 
events, use of these agents may not be appropriate in 
certain patients, and should warrant close scrutiny and 
vigilance by medical providers and caretakers.
Conclusion
The SGLT-2 inhibitors are a novel class of oral anti- 
hyperglycemic agents that have been shown to decrease 
HbAlc values in patients with T2DM. These drugs 
may be used as adjunct treatment with other oral anti- 
hyperglycemic agents belonging to the biguanide, 
sulfonylurea, and DPP-4 inhibitor drug classes. Studies 
suggest HbAlc decreases may be more clinically relevant 
in patients with higher HbAlc values. The safety and 
tolerability of SGLT-2 inhibitors has not been elucidated 
in older patients. Although reports of SGLT-2 inhibitors 
negatively affecting renal clearance are limited, and no 
significant differences in the occurrence of hypotension 
and volume-related complications were observed in 
clinical trials, elderly patients may be at greater risk for 
developing these adverse effects. Frequent monitoring of 
renal function, volume status, and blood pressure may be 
required to ensure safe medication use. Caution, clinical
prudence, and careful weighing of benefits versus risks is 
recommended when use of these agents is contemplated 
in these patients.
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